Rahul Khurana: Intravitreal Injections a Difficult Treatment Choice but Often Better Than Blindness

Video

The discussion of intravitreal injections may not be an easy one for doctors to have with their patients, but when the full treatment picture is explained it can show how the benefits outweigh other potential issues.

The discussion of intravitreal injections may not be an easy one for doctors to have with their patients, but when the full treatment picture is explained it can show how the benefits outweigh other potential issues.

Rahul N. Khurana, MD, from Northern California Retina Vitreous Associates, said that while diagnosing conditions like central retinal vein occlosion can be done by most eyecare professionals the treatment, especially when it comes to injections, should only be done by specialists with experience in the field. Khurana also said that communication from diagnosis through treatment can often make a big difference in how receptive a patient is to the process as a whole.

Recent Videos
A panel of 3 experts on dry eye
A panel of 3 experts on RVO
HCPLive Five at ASRS 2024 | Image Credit: HCPLive
Jordana Fein, MD: Pre-Dose IOP Outcomes After Aflibercept 8 mg for DME | Image Credit: LinkedIn
Diana Do, MD: Impact of Baseline BCVA on Aflibercept 8 mg Outcomes in DME | Image Credit: Stanford University
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
© 2024 MJH Life Sciences

All rights reserved.